China SXT Pharmaceuticals filings document foreign private issuer disclosures for a Nasdaq-listed specialty pharmaceutical company focused on Traditional Chinese Medicine Pieces and TCM Homologous Supplements. The company’s Form 6-K reports cover material events, securities purchase agreements, registered direct offerings, Class A ordinary shares, pre-funded warrants, and shelf registration references tied to its capital-raising activity.
The filings also record shareholder-meeting materials, proxy documentation, amendments to the memorandum and articles of association, and the creation of a dual-class share structure with Class A Ordinary Shares and Class B Ordinary Shares. These disclosures frame SXTC’s governance, voting rights, security structure, offering documents, and related legal opinions as a British Virgin Islands company reporting under Form 20-F status.
China SXT Pharmaceuticals, Inc. (SXTC) completed a registered direct offering of 8,000,000 units on October 9, 2026, at $1.50 per Unit. Each Unit comprised one Class A ordinary share or, in lieu of a share, one pre-funded warrant to purchase one Class A ordinary share, plus one ordinary warrant. Gross proceeds to the company were expected to be approximately $12,000,000 before placement-agent fees and other offering expenses, excluding proceeds that may be received from warrant exercises.
Each ordinary warrant has an initial exercise price of $2.75 per Class A ordinary share and is exercisable from issuance through the one-year anniversary of issuance. Cashless exercise is available if, at the time of exercise, no effective registration statement covers issuance of the underlying shares. Holders may also elect a zero exercise price option under which up to 72,000,000 Class A ordinary shares may be issuable in aggregate, subject to the warrant terms. Investors have an additional purchase right for up to $12,000,000 of securities on the same terms during the 30-day period after closing. Univest Securities, LLC acted as placement agent on a reasonable best efforts basis, for a fee of 7.0% of gross proceeds and expense reimbursement capped at $50,000.
China SXT Pharmaceuticals, Inc. is offering up to 8,000,000 Units at $1.50 each and registering up to 72,000,000 Class A Ordinary Shares underlying 8,000,000 Ordinary Warrants. Each Unit includes one Class A Ordinary Share or one Pre-Funded Warrant in its place, plus one Ordinary Warrant. The Over-Allotment Option covers up to 8,000,000 additional Units and up to 72,000,000 additional underlying shares; investors may acquire up to $12,000,000 of securities on the same terms during the 30-day period after closing. China SXT estimates net proceeds of approximately $11.06 million for working capital and general corporate purposes.
Ordinary Warrants are immediately exercisable at an initial $2.75 per share and expire on the one-year anniversary of the initial exercise date. They permit cashless exercise under specified circumstances and zero-price exercise when the Low Price is below the exercise price. If the Low Price equals the $0.50 Floor Price and all base warrants use zero-price exercise, up to 72,000,000 Class A Ordinary Shares could be issued; China SXT does not expect cash proceeds from warrant exercises.
China SXT is a British Virgin Islands holding company conducting its China business through subsidiaries and a variable interest entity under contractual arrangements. It says the VIE agreements have not been tested in a Chinese court and PRC regulatory uncertainty could affect its operations and U.S. listing.
China SXT Pharmaceuticals, Inc. (SXTC) announced a registered direct offering under a definitive agreement for 8,000,000 Class A ordinary shares (or pre-funded warrants in lieu) at $1.50 per share, together with 8,000,000 warrants. The company expects approximately $12 million in gross proceeds before placement agent fees and other offering expenses payable by the company. A revised press release corrects the warrants’ initial exercise price to $2.75 per Class A ordinary share.
The warrants will be immediately exercisable upon issuance and have a one-year term from issuance; each has a zero cash exercise option permitting the holder to acquire up to 9 Class A shares. Investors also have an additional purchase right for up to $12 million of securities on the same terms during the 30-day period after closing. The offering is expected to close on or about October 9, 2026, subject to customary closing conditions. Univest Securities, LLC is acting as sole placement agent. The offering is made under the company’s Form F-3 shelf registration statement, which became effective on December 1, 2025.
China SXT Pharmaceuticals, Inc. terminated a proposed private placement on October 8, 2026, before closing. An agreement entered October 7 proposed 3,000,000 Class A ordinary shares and warrants to purchase 3,000,000 Class A ordinary shares, with each warrant exercisable for one share at $1.00; gross proceeds would have been $3 million.
The company and the purchasers agreed to terminate the offering. No shares or warrants were issued, and all obligations under the Securities Purchase Agreement and the warrants were terminated.
China SXT Pharmaceuticals, Inc. (SXTC) has filed an amended Form F-3 to register 157,500,000 Class A Ordinary Shares for resale by Smart Mart Limited. These shares may be issued to Smart Mart to satisfy balances of pre-funded "Pre-Paid Purchases" under a July 3, 2026 Securities Purchase Agreement with up to $31,500,000 aggregate principal (before a $1,500,000 original issue discount). The resale is subject to a 9.99% beneficial ownership cap.
The conversion price per share is the lower of 50% of the Nasdaq closing price on signing or 50% of the lowest closing price in the prior 180 trading days, but not below a $0.20 floor price. SXTC receives no proceeds from resales, but previously received cash from the Pre-Paid Purchases; Smart Mart will receive sale proceeds, while SXTC bears registration costs. The commitment period runs until the earlier of two years from initial closing, aggregate purchase proceeds of $30,000,000, or termination. The filing highlights substantial dilution risk, potential Nasdaq delisting risk, PRC regulatory and VIE-structure uncertainties, and HFCAA-related delisting risk for this China-based holding company.
China SXT Pharmaceuticals, Inc. (SXTC) reports an amendment to its financing arrangement with an institutional investor. The company previously agreed to issue one or more pre-paid purchases with an aggregate principal amount of up to $31,500,000 (before a $1,500,000 original issue discount) for purchases of Class A ordinary shares at a price not below a $0.20 per-share floor.
After a 1-for-80 share consolidation of the Class A ordinary shares on August 10, 2026, the floor price was adjusted to $16.00 per share under the pre-paid purchase terms. On August 27, 2026, the company and the investor executed Amendment No. 1 to reduce the floor price back to $0.20 per share. In connection with this amendment, the company filed Amendment No. 1 to its Form F-3 registration statement, and this report is incorporated by reference into the company’s existing Form S-8 and Form F-3 registration statements.
China SXT Pharmaceuticals, Inc. completed a registered direct offering of 4,500,000 Units, each consisting of one Class A ordinary share and one common warrant, at $2.00 per Unit, generating aggregate gross proceeds of $9,000,000 before fees and expenses.
Each Warrant is immediately exercisable at $3.20 per Class A ordinary share and expires one year after issuance, with cashless exercise and a "zero exercise price" option under which up to 63,000,000 Class A ordinary shares may be issued in total under the Warrants. Univest Securities, LLC acted as placement agent, earning a 7.0% cash fee on gross proceeds plus up to $50,000 of expenses, in an offering conducted under the company’s effective Form F-3 shelf registration.
China SXT Pharmaceuticals Inc. is conducting a primary offering of up to 4,500,000 Units, each consisting of one Class A Ordinary Share and one Ordinary Warrant, at $2.00 per Unit, for aggregate gross proceeds of up to $9,000,000. The company is also registering up to 63,000,000 Class A Ordinary Shares issuable upon exercise of the 4,500,000 Ordinary Warrants, which carry a $3.20 initial exercise price, cashless exercise, and a “zero price exercise” feature tied to VWAP and a $0.40 Floor Price.
The company expects to receive approximately $8.28 million in net proceeds after placement fees and expenses, to be used for working capital and general corporate purposes. A 7.0% cash fee will be paid to Univest Securities, LLC as placement agent. There is no minimum offering amount and no escrow arrangement.
Class A Ordinary Shares outstanding were 38,218,077 before the offering and are projected to reach 105,718,077 assuming full issuance of Units and zero price exercise of all Warrants, implying substantial potential dilution. The company highlights legal and operational risks from its China-based VIE structure and evolving PRC and U.S. regulations, including the HFCAA.
China SXT Pharmaceuticals, Inc. filed a Form F-3 prospectus to register the resale of up to 157,500,000 Class A Ordinary Shares by Smart Mart Limited. Those shares represent the quotient of a $31,500,000 aggregate principal Pre-Paid Purchase program (less a $1,500,000 original issue discount) and are subject to a 9.99% beneficial ownership cap per the Securities Purchase Agreement.
The Selling Shareholder will receive all proceeds from resales and the Company will not receive proceeds but will pay registration costs. The purchase-price mechanics use a 50% discount to specified Nasdaq closing-price measures with a $0.20 floor price. The prospectus discloses VIE structure risks, PRC regulatory uncertainty and HFCAA inspection considerations. As of the prospectus date, 38,218,077 Class A Ordinary Shares were issued and outstanding.